ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
US Tech 100
17,446.00
2.17%
Dow Jones
38,675.68
1.18%
Brent Oil
82.765
0.00%
Bitcoin
63,918.18
1.64%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Kiniksa Pharmaceuticals Ltd (KNSA) Quote

Kiniksa Pharmaceuticals Ltd

Kiniksa Pharmaceuticals Ltd (KNSA)

NASDAQ
20.08
0.70
(3.61%)
Closed May 04 4:00PM
Delayed by 15 minutes
20.08
0.00
(0.00%)
After Hours: 5:30PM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
20.08
Bid
19.40
Ask
20.65
Volume
403,855
19.62 Day's Range 20.40
12.65 52 Week Range 22.10
Market Cap
1.42B
Previous Close
19.38
Open
20.13
Last Trade
32
@
19.96
Last Trade Time
Financial Volume
$ 8,071,007
VWAP
19.9849
Average Volume (3m)
398,615
Shares Outstanding
70,615,022
Dividend Yield
-
PE Ratio
100.85
Earnings Per Share (EPS)
0.2
Revenue
270.26M
Net Profit
14.08M

About Kiniksa Pharmaceuticals Ltd

Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its clinical-stage product candidates include Rilonacept, for the treatment of recurre... Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its clinical-stage product candidates include Rilonacept, for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; Vixarelimab; and KPL-404. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.kiniksa.com
Headquarters
Hamilton, Bmu
Founded
1970
Kiniksa Pharmaceuticals Ltd is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker KNSA. The last closing price for Kiniksa Pharmaceuticals was $19.38. Over the last year, Kiniksa Pharmaceuticals shares have traded in a share price range of $ 12.65 to $ 22.10.

Kiniksa Pharmaceuticals currently has 70,615,022 shares outstanding. The market capitalization of Kiniksa Pharmaceuticals is $1.42 billion. Kiniksa Pharmaceuticals has a price to earnings ratio (PE ratio) of 100.85.

Kiniksa Pharmaceuticals (KNSA) Options Flow Summary

KNSA Options Flow

Overall Flow

Bullish

Net Premium

200k

Calls / Puts

100.00%

Buys / Sells

0.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

KNSA Latest News

More News

Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution

– ARCALYST® (rilonacept) Q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth –– ARCALYST 2024 expected net product revenue increased to $370 - $390 million ––...

April 23 2024
GlobeNewswire Inc.

Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024

HAMILTON, Bermuda, April 16, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 23, 2024...

April 16 2024
GlobeNewswire Inc.

Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart

– Abiprubart Phase 2b trial in Sjogren’s Disease planned to initiate in 2H 2024 –– Abiprubart Phase 2 Cohort 4 rheumatoid arthritis data further validate biological activity –– Abiprubart...

April 02 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

March 05 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

March 05 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

March 01 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

February 29 2024
Edgar (US Regulatory)

Form 8-K - Current report

February 28 2024
Edgar (US Regulatory)

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution

– ARCALYST® (rilonacept) Q4 2023 and full-year 2023 net product revenue of $71.2 million and $233.2 million, respectively – – ARCALYST 2024 net product revenue expected to be $360 - $380 million...

February 28 2024
GlobeNewswire Inc.

Form 144 - Report of proposed sale of securities

February 27 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
12.2412.556053811717.8420.417.4547874018.85343916CS
42.0711.493614658518.0120.416.5639420117.86876289CS
120.834.3116883116919.2522.116.5639861519.38704367CS
263.7823.190184049116.322.114.1242608818.40498522CS
527.3858.110236220512.722.112.6543638117.34629257CS
1563.3820.239520958116.722.17.3639421014.26687065CS
2605.4437.158469945414.64335.0135521815.32177568CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BENFBeneficient
$ 6.8001
(254.17%)
31.01M
SGBXSafe and Green Holdings Corporation
$ 5.49
(87.37%)
92.18M
SHOTWSafety Shot Inc
$ 0.45
(45.16%)
644
AIPArteris Inc
$ 8.185
(38.03%)
1.11M
RGFReal Good Food Company Inc
$ 0.85
(37.32%)
4.26M
MNDRMobile health Network Solutions
$ 3.33
(-84.91%)
18.76M
NUVOHoldco Nuvo Group DG Ltd
$ 2.00
(-57.54%)
1.04M
SPTSprout Social Inc
$ 28.82
(-40.15%)
13.47M
UNITUniti Group Inc
$ 4.441
(-26.35%)
21.07M
IPDNProfessional Diversity Network Inc
$ 1.29
(-24.12%)
662.59k
AAPLApple Inc
$ 183.38
(5.98%)
163.22M
SQQQProShares UltraPro Short QQQ
$ 11.08
(-5.94%)
154.59M
JAGXJaguar Health Inc
$ 0.3164
(7.91%)
142.47M
NKLANikola Corporation
$ 0.6526
(6.55%)
106.88M
SGBXSafe and Green Holdings Corporation
$ 5.49
(87.37%)
92.18M

KNSA Discussion

View Posts
DonDonDonDon DonDonDonDon 3 years ago
No bueno. I guess HGEN's lenzilumab is the best of the anti-GM-CSF drugs for Covid. Lenzilumab's trial showed 54% efficacy. It is guaranteed an EUA within a couple of weeks yet its stock is 20% below where it was a month ago. It dropped 2 days ago because they diluted 5 million shares to pay for manufacturing.

https://www.rheumatologyadvisor.com/home/general-rheumatology/mavrilimumab-outcomes-patients-with-severe-covid19-pneumonia-hyperinflammation/
👍️0
DonDonDonDon DonDonDonDon 3 years ago
It was recently discovered that the protein GM-CSF is the cytokine responsible for severe Covid and death. Kiniksa will surely get a government grant to do an additional trial. Here is a BBC article about the trial that determined that GM-CSF is key to Covid:

https://www.bbc.com/news/health-56352128

Here is an additional article stating that KNSA and HGEN are the two companies with the best GM-CSF drugs to combat Covid:

https://www.clinicaltrialsarena.com/comment/humanigens-and-kiniksas-anti-gm-csf-antibodies-likely-to-garner-a-place-for-nonventilated-covid-19-patients/
👍️0
Femto99 Femto99 3 years ago
PT= $30-40 (by or around March 31st)
https://msmoneymoves.com/2021/02/17/knsa-report/
👍️0
Femto99 Femto99 3 years ago
PDUFA Mar21
👍️0

Your Recent History

NASDAQ
KNSA
Kiniksa Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved